Article ; Online: Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
2021 Volume 35, Issue 3, Page(s) 373–374
MeSH term(s) | Adverse Drug Reaction Reporting Systems ; Biosimilar Pharmaceuticals/adverse effects ; Databases, Factual ; Humans ; Neoplasms/drug therapy ; United States ; United States Food and Drug Administration |
---|---|
Chemical Substances | Biosimilar Pharmaceuticals |
Language | English |
Publishing date | 2021-04-16 |
Publishing country | New Zealand |
Document type | Letter ; Comment |
ZDB-ID | 1364202-9 |
ISSN | 1179-190X ; 1173-8804 |
ISSN (online) | 1179-190X |
ISSN | 1173-8804 |
DOI | 10.1007/s40259-021-00476-9 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 4112: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.